Eloralintide (Elora)
Elora · LY3841136 · Long-acting amylin receptor agonist
An investigational once-weekly peptide designed to engage amylin-mediated appetite and metabolic signaling without incretin receptor agonism.
Mechanism
Selective amylin receptor agonist
Protocol studied in research
Study design shown in plain language. This is not a personal dosing recommendation.
263 adults with obesity, or overweight with a weight-related comorbidity, without type 2 diabetes
Community-Reported Research Schedules
Descriptive community patterns are separated from clearly labeled trial-derived reference rows. Neither is personal dosing guidance.
| Research context or phase | Amount per administration | Schedule total | Frequency | Timing | Administration | Evidence level |
|---|---|---|---|---|---|---|
| Phase 2 fixed-dose reference | 1, 3, 6, or 9 mg | 1–9 mg/week | Once weekly | Same day each week | Subcutaneous | Trial-derived reference |
| Phase 2 escalation reference | 3 → 6 → 9 mg | Escalated weekly dose | Once weekly | Same day each week | Subcutaneous | Trial-derived reference |
Important: Repetition in online communities does not establish product identity, safety, effectiveness, or an appropriate exposure. Route-specific schedules, half-life estimates and reported cycle lengths are shown for comparison only.
Example Reconstitution Protocol
A hypothetical concentration calculation for literacy and review—not preparation, administration, or dosing instructions.
Arithmetic for a hypothetical 10 mg research vial only: 3 mg equals 0.30 mL (30 units), 6 mg equals 0.60 mL (60 units), and 9 mg equals 0.90 mL (90 units). This does not reproduce Lilly's sponsor-controlled trial formulation.
Community reference: Phase 2 dose reportingImportant: Vial strength, diluent identity, compatibility, sterility, stability and beyond-use time are product-specific. Never infer them from this arithmetic example. Use manufacturer, pharmacy, study, or licensed-clinician instructions for an actual preparation.
Cycle & Supplies Planning
Phase-by-phase cycle math showing how long a vial lasts and the estimated supplies required.
No single, consistently reported subcutaneous amount-and-frequency pair is available for a responsible automatic supply calculation.
Planning boundary: These are arithmetic examples based on the displayed research schedule—not personal dosing or purchasing instructions. Confirm product format, compatibility, route, sterility, storage, and discard timing independently. U-100 units measure liquid volume, not potency.
Safety signal
Nausea and fatigue were the most common adverse events and varied by dose and escalation arm. The trial does not establish an approved treatment or self-use protocol.
Reported doses describe either a specific study or an unverified community pattern. Neither is personal medical guidance.